Please assess the completion status of the following clinical trial:

Trial Title: A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen~* Measurable disease as described in the protocol~* Received at least 1 prior line of therapy as described in the protocol~* Must meet prior antimyeloma treatment parameters, as described in the protocol, and includes:~* Received at least 2 consecutive cycles of lenalidomide or a lenalidomide-containing regimen~* Refractory to lenalidomide~* Exposed to a proteasome inhibitor (PI) alone or in combination with another agent~* Had a response of partial response (PR) or better to prior therapy based on the investigator's determination of response as defined by International Myeloma Working Group (IMWG) criteria~* Has t(11;14) status as described in the protocol and meets the following criteria:~* For Part 1: MM participants independent of cytogenetic profile~* For Part 2, Arm A: participant must be t(11;14) positive~* For Part 2, Arm B: participant must be t(11;14) negative~* An Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Adequate kidney, liver and hematologic laboratory values~Exclusion Criteria:~* Previous treatment with venetoclax or other BCL-2 inhibitors, or previous treatment with pomalidomide~* Known sensitivity to any IMiDs~* Allogenic or syngeneic stem cell transplant within 6 months before the first dose of study drug or active ongoing graft versus host disease~* Autologous stem cell transplant within 12 weeks before the first dose of study drug~* Known meningeal involvement of MM

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Dose Escalation (Type: EXPERIMENTAL): Venetoclax (400 mg oral \[PO\], once daily \[QD\]) administered with pomalidomide (4 mg PO, QD) and dexamethasone (40 mg once weekly \[qw\]) in 28-day cycles until documented disease progression, documented unacceptable toxicity, withdrawal of consent, or the participant met other criteria for discontinuation per study protocol
- Part 2: Dose Expansion, t(11;14) positive (Type: EXPERIMENTAL): Participants positive for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral \[PO\], once daily \[QD\]) and dexamethasone (40 mg once weekly \[qw\])
- Part 2: Dose Expansion, t(11;14) negative (Type: EXPERIMENTAL): Participants negative for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral \[PO\], once daily \[QD\]) and dexamethasone (40 mg once weekly \[qw\])

Based on this trial design, predict the completion outcome and termination type (if applicable).